Scholar Rock logo

Scholar Rock

SRRK | NASDAQ
Chart Builder DCF Calculator
$44.54
+$1.34 (+3.09%)
At close: Nov 16, 2026, 4:00 PM ET
$44.54
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
+3.09%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
30.4
Fundamentals Weak
Market Sentiment Neutral
Moat Narrow
Sector Rank #787/1021 (Top 77%)

Key Statistics

Market Data

Market Cap $5.9B
1D Range
42.77 45.61
52W Range
36.47 60.04

Valuation (TTM)

PE -13.83
PB 34.95
EV/EBITDA -14.27

Valuation (NTM)

Forward PE N/A
Forward PEG 1.92
Price Target $71.00
Loading financial charts...

Profile

Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor sign...

Sector Healthcare
Industry Biotechnology
Employees 289
IPO Date May 25, 2018
Fiscal Year January - December

Latest News

Scholar Rock Holding Corporation (SRRK) Presents at UBS Global Biopharma Conference 2026 Transcript

13 hours ago · seekingalpha.com

Scholar Rock Holding Corporation (SRRK) Presents at UBS Global Biopharma Conference 2026 Transcript
What Scholar Rock (SRRK) Said on Its Q3 Earnings Call

6 days ago · marketbeat.com

What Scholar Rock (SRRK) Said on Its Q3 Earnings Call
Scholar Rock Holding Corporation (SRRK) Q3 2026 Earnings Call Transcript

6 days ago · seekingalpha.com

Scholar Rock Holding Corporation (SRRK) Q3 2026 Earnings Call Transcript
Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Beats Revenue Estimates

6 days ago · zacks.com

Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Beats Revenue Estimates
Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play

2 months ago · seekingalpha.com

Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play
Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript

2 months ago · seekingalpha.com

Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy

2 months ago · benzinga.com

Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial

2 months ago · reuters.com

Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

2 months ago · benzinga.com

Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

2 months ago · businesswire.com

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

Earnings

Latest Earnings
Nov 10, 2026
EPS
-$0.81
Beat +4.39%
REV
$600K
Beat +97.41%
Next Earnings
Mar 2, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
12
Consensus
Buy
Price Target
$71.00
Upside
+59.41%
Buy (10)
Hold (2)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.